Health Insurer Strategies to Reduce Specialty Drug Spending-Copayment Adjustment and Alternative Funding Programs

Autumn D Zuckerman; Megan P Schneider; Stacie B Dusetzina

doi:10.1001/jamainternmed.2023.1829

Health Insurer Strategies to Reduce Specialty Drug Spending-Copayment Adjustment and Alternative Funding Programs

JAMA Intern Med. 2023 Jul 1;183(7):635-636. doi: 10.1001/jamainternmed.2023.1829.

Authors

Autumn D Zuckerman¹, Megan P Schneider¹, Stacie B Dusetzina²

Affiliations

¹ Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tennessee.
² Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee.

PMID: 37252717
DOI: 10.1001/jamainternmed.2023.1829

No abstract available

Plain language summary

This Viewpoint describes programs intended to help patients with commercial insurance that, instead, employers, health plans, and other payers use to reduce their spending on specialty drugs.

MeSH terms

Cost Sharing
Drug Costs
Health Benefit Plans, Employee*
Health Expenditures
Humans
Insurance Carriers*
United States